CAJ | 학술논문

目的探讨慢性乙型肝炎患者接受恩替卡韦抗病毒治疗前后细胞免疫学功能的变化.方法纳入对象为慢性乙型肝炎患者(CHB)50例,分为治疗组30例,对照组20例,治疗组接受恩替卡韦抗病毒治疗12个月,对照组未接受核苷类似物或干扰素抗病毒治疗.通过流式细胞术动态分析两组患者外周T细胞亚群和CD4+ CD25+ Foxp3+调节性T细胞的表型和频率变化.结果接受恩替卡韦治疗的患者,与治疗前比较,治疗后3个月、6个月和12个月其CD4 T细胞、CD4/CD8逐渐增高和CD4+ CD25+ Foxp3+调节性T细胞比例逐渐显著性降低,差异有统计学意义(P＜0.05);而对照组观察前后差异无统计学意义(P＞0.05).治疗组治疗后12个月,其调节性T细胞的下降幅度与血清HBV DNA的下降水平呈显著正相关(r=0.65,P＜0.01).结论恩替卡韦在有效抗病毒治疗同时具有改善患者的细胞免疫功能.
목적 탐토만성을형간염환자접수은체잡위항병독치료전후세포면역학공능적변화.방법 납입대상위만성을형간염환자(CHB)50례,분위치료조30례,대조조20례,치료조접수은체잡위항병독치료12개월,대조조미접수핵감유사물혹간우소항병독치료.통과류식세포술동태분석량조환자외주T세포아군화CD4+ CD25+ Foxp3+조절성T세포적표형화빈솔변화.결과 접수은체잡위치료적환자,여치료전비교,치료후3개월、6개월화12개월기CD4 T세포、CD4/CD8축점증고화CD4+ CD25+ Foxp3+조절성T세포비례축점현저성강저,차이유통계학의의(P＜0.05);이대조조관찰전후차이무통계학의의(P＞0.05).치료조치료후12개월,기조절성T세포적하강폭도여혈청HBV DNA적하강수평정현저정상관(r=0.65,P＜0.01).결론 은체잡위재유효항병독치료동시구유개선환자적세포면역공능.
Objective To explore the role of Entecavir in CD4 * T cells and CD4 + CD25 + Foxp3 + regulatory T cells of patients with chronic hepatitis B.Methods Patients with chronic active hepatitis B (CAH,n =50) were divided into Entecavir treatment group (n =30) and controls (n =20).The entecavir treatment group and the controls were followed up for 12 months.The frequency and phenotype of peripheral CD4 + and CD4 + CD25 + Foxp3 + T cells were detected by flow cytometry.Results Patients with CHB receiving entecavir treatment for 3 months,6 months and 12months exhibited significantly higher frequency of CD4 + T cells and CD4/CD8 ratio as opposed to those of baseline levels(P ＜0.05).The frequency of CD4 +CD25 + Foxp3 + T cells from the patients receiving entecavir treatment for 3 months,6 months and 12 months was significantly decreased compared with that of basline level(P ＜ 0.05).However,the frequency of CD4 T cells and CD4 + CD25 + Foxp3 + T cells,as well as CD4/CD8 ratio of the control group following up for 12 months displayed no significant differences compared with its baseline levels.The serum HBV DNA level from the baseline to Entecavir treatment for 12 months was correlated with the frequency of CD4 + CD25 +Foxp3 * T cells from the baseline to Entecavir treatment for 12 months.Conclusions Entecavir not only can effectively suppress HBV replication,but also simultaneously improve the cellular immune function of chronic hepatitis B.